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Abstract
Introduction. During previous viral pandemics, reported co- infection rates and implicated pathogens have varied. In the 1918 
influenza pandemic, a large proportion of severe illness and death was complicated by bacterial co- infection, predominantly 
Streptococcus pneumoniae and Staphylococcus aureus.
Gap statement. A better understanding of the incidence of co- infection in patients with COVID-19 infection and the pathogens 
involved is necessary for effective antimicrobial stewardship.
Aim. To describe the incidence and nature of co- infection in critically ill adults with COVID-19 infection in England.
Methodology. A retrospective cohort study of adults with COVID-19 admitted to seven intensive care units (ICUs) in England up 
to 18 May 2020, was performed. Patients with completed ICU stays were included. The proportion and type of organisms were 
determined at <48 and >48 h following hospital admission, corresponding to community and hospital- acquired co- infections.
Results. Of 254 patients studied (median age 59 years (IQR 49–69); 64.6 % male), 139 clinically significant organisms were 
identified from 83 (32.7 %) patients. Bacterial co- infections/ co- colonisation were identified within 48 h of admission in 14 
(5.5 %) patients; the commonest pathogens were Staphylococcus aureus (four patients) and Streptococcus pneumoniae (two 
patients). The proportion of pathogens detected increased with duration of ICU stay, consisting largely of Gram- negative bac-
teria, particularly Klebsiella pneumoniae and Escherichia coli. The co- infection/ co- colonisation rate >48 h after admission was 
27/1000 person- days (95 % CI 21.3–34.1). Patients with co- infections/ co- colonisation were more likely to die in ICU (crude OR 
1.78,95 % CI 1.03–3.08, P=0.04) compared to those without co- infections/ co- colonisation.
Conclusion. We found limited evidence for community- acquired bacterial co- infection in hospitalised adults with COVID-19, but 
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INTRODUCTION
During previous viral pandemics, reported co- infection rates 
and implicated pathogens have varied. In the 1918 influenza 
pandemic an estimated 95 % of severe illness and death was 
complicated by bacterial co- infection, predominantly Strep-
tococcus pneumoniae and Staphylococcus aureus [1].
As of 3 September 2020, over 25 million cases and 850, 000 
deaths due to COVID-19 infection have been reported world- 
wide [2]. The symptoms associated with COVID-19 infection 
are relatively non- specific. Fever and lower respiratory tract 
symptoms, such as a cough or breathlessness, are common in 
patients who require hospital care and radiological changes 
consistent with pneumonia are evident in up to 97 % of these 
patients [3]. Confirmation of acute COVID-19 infection is 
reliant on a positive SARS- CoV-2 polymerase chain reaction 
(PCR) test result. The immune response to SARS- CoV2 infec-
tion includes a rise in IL-6 and C- reactive protein (CRP), with 
higher levels associated with more severe disease [4, 5].
The contribution of secondary or co- pathogens to COVID-19 
infection is not well understood. The lack of an effective anti- 
viral agent against SARS- CoV2 combined with challenges in 
differentiating secondary bacterial co- infection from severe 
COVID-19 infection alone, has fostered the widespread use 
of empirical antibiotics in the immediate management of 
patients hospitalised with COVID-19 infection. Over the 
spring wave of the pandemic, 83.1 % of hospitalised patients 
received empirical antibiotic treatment [6].
The utility of specific biomarkers such as procalcitonin to 
guide antibiotic therapy in severe respiratory tract infection, 
and specifically COVID-19 infection, is as yet uncertain [7, 8]. 
In the meantime, a better understanding of the incidence of 
co- infection in patients with COVID-19 infection and the 
pathogens involved is necessary for effective antimicrobial 
stewardship. The primary objective of this study was to 
determine the rate of co- infection in critically ill adults with 
COVID-19 infection in England. Secondary aims were to 
describe the organisms, the characteristics of patients with 




A retrospective observational multicentre study of 
co- infection in adults with confirmed COVID-19 requiring 
intensive care unit (ICU) admission was performed. Seven 
acute hospitals from across England participated in the study 
including large (>1,000 beds) tertiary hospitals and medium 
(500–1,000 beds) district hospitals: Nottingham University 
Hospitals NHS Trust, Newcastle Upon Tyne Hospitals NHS 
Foundation Trust, Brighton and Sussex University Hospitals 
NHS Trust, Guy’s and St Thomas’ NHS Foundation Trust, 
Salford Royal NHS Foundation Trust, University Hospitals 
of Derby and Burton NHS Foundation Trust and University 
College London Hospitals NHS Foundation Trust.
Study population
Case inclusion criteria were adults aged >16 years with 
completed ICU admissions (discharged from or died whilst 
in ICU) for COVID-19 pneumonia (i.e. requiring Level 2 or 
Level 3 care according to the classification by the Intensive 
Care Society, UK) from disease emergence to 18 May 2020. 
SARS- CoV-2 was confirmed using reverse transcriptase- 
polymerase chain reaction (RT- PCR) from a respiratory spec-
imen. Participating sites were asked to enter data for either: (1) 
all identified patients, or (2) a random selection of at least ten 
patients from across their eligible cohort. Where more than 
one critical care area existed at a participating site, a random 
selection from across areas was requested to avoid selection 
bias. Exclusion criteria were defined as: COVID-19 infection 
diagnosed >48 h after hospital admission or a hospital admis-
sion in the last 14 days (hospital- acquired COVID-19) and 
patients transferred into ICU from a different hospital. Only 
the first admission to ICU was included.
Data collection
Personal information was removed at the point of partici-
pating site data entry onto a secure online database platform 
(REDCap Cloud). Data were gathered from electronic medical 
records. Fields collected were: demographics (age, gender, 
ethnicity, presence or absence of co- morbidity as defined 
in the Intensive Care National Audit and Research Centre 
(ICNARC) report on COVID-19 in critical care (Online 
Resource 1, available in the online version of this article) and 
type 2 diabetes mellitus); hospital admission details (date, 
days of symptom onset prior to admission and radiology find-
ings); ICU details (date of admission, mechanical ventilation 
during the first 24 h, advanced respiratory support (Online 
Resource 1), acute physiology and chronic health evaluation 
(APACHE II) score and outcomes); antibiotics received and 
all microbiology test results to the end of the ICU admission 
(including any identified antimicrobial resistance).
Definitions
Diagnostic microbiology tests were performed as per 
standard testing protocols within NHS laboratories at indi-
vidual participating sites. Microbiology results included in 
the analysis were: standard culture (blood, sputum, tracheal- 
aspirate, bronchoalveolar lavage (BAL), urine) and validated 
culture- independent tests such as respiratory viral PCR 
(see Online Resource 2) and urinary antigens. Co- infection 
was defined as present if a likely pathogen was identified 
in a clinical sample taken for diagnostic purposes. Culture 
results were excluded if they were considered to represent 
contamination or colonisation. Specifically, this applied to 
the following situations: blood cultures yielding common 
skin contaminants in a single sample (coagulase- negative 
staphylococci, Micrococcus spp., viridans group streptococci, 
Propionibacterium spp., Corynebacterium spp., Bacillus spp.) 
without a concurrent positive culture from an indwelling 
line tip [9–11], Candida spp. cultured from respiratory 
and urinary catheter samples [12, 13], respiratory samples 
yielding Gram- positive organisms typically present in the 
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oropharyngeal flora [14], growth of Enterococcus spp. in a 
single catheter urinary specimen [15]. Despite this effort, 
culture results from some non- sterile respiratory samples 
may represent colonisation, hence the term co- infection/ 
co- colonisation is used for respiratory samples. Radiology 
findings were defined based on the COVID-19 British Society 
of Thoracic Imaging reporting template [16]. Where both 
chest CT and CXR findings were available, chest CT findings 
were prioritised.
Statistical analysis
Demographics, clinical and disease characteristics were 
described using appropriate descriptive statistics for: (i) 
those with co- infection, and (ii) those without co- infection. 
Characteristics of patients in the study were also compared 
with the patients in the Intensive Care National Audit and 
Research Centre (ICNARC) report on COVID-19 in critical 
care, 22 May 2020. The proportion of co- infection (%) was 
determined at three time points: on admission, within 
48 h, and during ICU admission (from day of ICU admis-
sion to ICU discharge or death in ICU). The co- infection 
rate was calculated per 1000 person- days based on the first 
co- infection detected in hospital per patient (person- time 
was determined from date of hospital admission to date of 
first co- infection, date of discharge from ICU or date of death 
in ICU, whichever came first for each patient). Univariate 
logistic regression analyses were conducted to determine the 
association between selected variables (age, gender, study site, 
ethnicity and co- morbidities) and the odds of (a) developing 
co- infection during admission, and (b) co- infection and 
mortality in ICU. Competing- risks regression analysis was 
conducted to assess if patients with co- infection had a longer 
length of hospital stay (from hospital admission to the end of 
ICU admission) than those without co- infection, with death 
as a competing- event. Co- pathogens were described sepa-
rately for bacterial, viral and fungal infections. The proportion 
of bacterial co- pathogens with antimicrobial resistance was 
recorded.
An analysis of type of pathogens identified at different time 
points from admission was performed (≤48 h and >48 h 
following admission) to identify those with community 
Fig. 1. Flowchart of study population. aSee Online Resource 3 in the supplementary material for exact breakdown.
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Number of patients 171 (67.3) 83 (32.7) 9026
Age *
  18–49 47 (27.5) 17 (20.5)
  50–64 51 (29.8) 42 (50.6)
  65–74 47 (27.5) 19 (22.9)
  75–84 26 (15.2) 5 (6.0)
Gender [N=9022]
  Male 106 (62.0) 58 (69.9) 6403 (71.0)
  Female 65 (38.0) 25 (30.1) 2619 (29.0)
Ethnicity [N=8185]
  White 108 (63.2) 44 (53.0) 5468 (66.8)
  Black 13 (7.6) 10 (12.1) 1245 (15.2)
  Asian 16 (9.4) 5 (6.0) 797 (9.7)
  Mixed 3 (1.8) 2 (2.4) 138 (1.7)
  Other 4 (2.3) 3 (3.6) 537 (6.6)
  §BAME 36 (21.1) 20 (24.1) –
  Unknown 27 (15.8) 19 (22.9) –
Co- morbidities [N=8777]
  Cardiovascular 3 (1.8) 0 (0.0) 42 (0.5)
  Respiratory 0 (0.0) 2 (2.4) 74 (0.8)
  Renal 3 (1.8) 2 (2.4) 144 (1.6)
  Liver 0 (0.0) 0 (0.0) 33 (0.4)
  Metastatic disease 0 (0.0) 0 (0.0) 38 (0.4)
  Haematological malignancy 6 (3.5) 1 (1.2) 144 (1.6)
  Immunocompromised 11 (6.5) 2 (2.4) 295 (3.4)
  Type 2 diabetes mellitus 47 (27.5) 19 (22.9) n/a
Indicator of acute severity
  Mechanically ventilated within first 24 h 5298 (62.8)b
  APACHE II Score, mean (SD) 13.3 (5.6) 14.2 (5.5) 14.7 (5.3)c







   ≤13.3 kPa (<100 mmHg) 49 (28.7) 24 (28.9) 2982 (36.8)
   >13.3 and ≤26.7 kPa (100–200 mmHg) 92 (53.8) 41 (49.4) 3961 (48.9)
   >26.7 kPa (>200 mmHg) 30 (17.5) 18 (21.7) 1161 (14.3)
LOS from hospital admission to the end of ICU admission (days), median 
(IQR)
  Survivors 9 (4–14) 22 (17–27) n/a
  Non- survivors 7 (4–12) 17 (11–20)
a, Intensive Care National Audit and Research Centre (ICNARC) report from 22 May 2020.
*Median age=60 (51–68).
Denominators: b, N=8433, c, N=8648 and d, N=8104.
§ BAME is the total of Black, Asian, Mixed andOther ethnicities
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vs hospital- acquired co- infection. Pathogens identified 
within 48 h of hospital admission were listed by type of 
test performed. A sub- analysis of the hospital- acquired 
co- infection was performed to identify the type of patho-
gens detected early (3–7 days into hospital admission) and 
late (>7 days into hospital admission). Statistical analyses 
were performed using Stata MP/15.1.
RESULTS
Of 579 eligible patients during the study period, 254 patients 
with completed ICU episodes were studied (Fig. 1).
The median age of the study cohort was 59 years (IQR 
49–69, range 19–84) and 164 (64.6 %) patients were male; 
similar to corresponding data from the ICNARC cohort 
(Table 1) [17]. Patients were admitted to hospital between 
21 Feb 2020 and 1 May 2020. The median time from onset of 
symptoms to admission was 7 days (IQR 5–10). The median 
time from hospital admission to ICU admission was 1 day 
(IQR 0–2). Antibiotics were prescribed to 35 (13.8 %) 
patients before hospital admission and to 228 (89.8 %) 
patients within 48 h of admission. Throughout the course 
of admission, 241 (94.9 %) of patients received antibiotics 
at some point.
The overall median length of stay (LOS) in ICU was 9 days 
(IQR 4–17); 10 days (IQR 4–18) for survivors and 9 days (IQR 
5–15) for non- survivors. One hundred and fifty- one patients 
(59.5 %) were mechanically ventilated within 24 h of admis-
sion, and 158 patients (62.2 %) received advanced respiratory 
support (invasive ventilation, CPAP via trans- laryngeal tube, 
extracorporeal respiratory support) during admission. Of 
those who were discharged from ICU (n=172 patients), two 
patients (1.2 %) died in hospital, 147 patients (85.5 %) were 
discharged from hospital and 23 patients (13.4 %) remained 
in hospital at the end of the study.
All patients had either a CXR (n=246 patients) and/or a 
chest CT scan (n=74 patients). Classic/ probable COVID-19 
radiographic changes were recorded in 209 patients (82.3 %), 
five (2 %) had normal imaging, 27 (10.6 %) had indeterminate 
changes and 13 (5.1 %) had non- COVID19 findings.
In total, co- infection/ co- colonisation was identified in 83 
(32.7 %) patients from hospital admission to the end of ICU 
stay; median time to co- infection/ co- colonisation was 9 days 
(IQR 6–14). The list of identified potential pathogens and 
contaminants from standard cultures (blood, BAL, sputum 
and tracheal aspirate) is available in Online Resource 4. On 
the day of admission, potential co- pathogens were identi-
fied in four patients (1.6 %), rising to 14 (5.5 %) patients 
within the first 48 h of hospital admission. Fifteen potential 
pathogens were identified from 14 patients within 48 h; 14 
bacterial and one viral pathogen (Table 2). None of these 
potential pathogens were identified from blood culture. In 
a sensitivity analysis excluding the hospital which contrib-
uted a third of cases, the 48 h co- infection/ co- colonisation 
rate remained similar (Online Resource 5). The commonest 
potential co- pathogen within 48 h of hospital admission was 
S. aureus, three methicillin- susceptible (MSSA) and one 
methicillin- resistant S. aureus (MRSA) (four patients). Two 
positive Mycoplasma IgG/ IgM tests in separate patients were 
deemed false positives and excluded from the analysis. The 
number of tests performed within 48 h of hospital admission 
are listed in Online Resource 6, by type of tests and study site. 
For bacterial co- pathogens, the antimicrobial susceptibilities 
are described in Online Resource 7 in the supplementary 
material.
Beyond 48 h of hospital admission to the end of ICU stay, 
124 potential co- pathogens were identified in 77 (30.3 %) 
patients; 29 potential pathogens from days 3–7 and 95 poten-
tial pathogens from day 8 onwards (Fig. 2). The co- infection/
co- colonisation rate >48 hours after admission was 27.0 per 
1000 person- days (95 % CI 21.3–34.1). All were bacterial 
pathogens (n=122) except for two fungal organisms. The 
commonest potential co- pathogens identified were Gram- 
negative bacteria, including Klebsiella spp. (23 patients) and 
Escherichia coli (20 patients). No viral co- pathogens were 
detected. Of the two fungal co- pathogens, one was Aspergillus 
fumigatus from a tracheal aspirate culture obtained on day 5 
in a 54 year old male. The other was Candida parapsilosis from 
Table 2. Organisms identified within 48 h of hospital admission
Type of test Potential pathogens No of pathogens
Tracheal aspirate or 
sputum culture
  
  Escherichia coli 1
  Pseudomonas spa 1
  Pseudomonas aeruginosa 1
  Enterobacter cloacae complex 
(AmpC)
1
  Staphylococcus aureus 
(MSSA)a
2
BAL PCR/ culture   
  Staphylococcus aureus (MSSA 
and MRSA)b
2
  Klebsiella pneumoniae 1




MSU Escherichia coli 2




a, Pathogens identified on the day of admission (Pseudomonas sp, 
one out of two MSSA and one out of two S. pneumoniae identified, 
and Metapneumovirus), total=4.
b, One out of two organisms was Methicillin- resistant 
Staphylococcus aureus (MRSA). The same patient also had MRSA in 
pleural fluid culture after 48 h into hospital admission.
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a blood culture taken at day 7 in a 55 year old lady. Neither 
patient had any pre- existing co- morbidities.
On univariate analyses, patients aged 50–64 years were more 
likely to have a co- infection/ co- colonisation than those 
aged 18–49 years. No other significant association was found 
(Table 3). Patients with co- infections/ co- colonisation were 
more likely to die in ICU (with coinfections/ co- colonisation, 
n=34 vs without coinfections/ co- colonisation, n=48, crude 
OR 1.78, 95 % CI 1.03–3.08, P=0.04) and had a longer hospital 
LOS (measured from admission to hospital to the end of ICU 
admission, subhazard ratio (likelihood of discharge from 
ICU)=0.53, 95 % CI 0.39–0.71, P<0.001).
DISCUSSION
Principal findings
Bacterial co- infection/ co- colonisation within 48 h of hospital 
admission for COVID-19 infection in adults was uncommon; 
1.6 % on admission and 5.5 % within 48 h. The commonest 
pathogens identified within the first 48 h of hospital admis-
sion were Staphylococcus aureus and Streptococcus pneumo-
niae. The proportion of pathogens detected increased with 
duration of ICU stay and consisted largely of Gram- negative 
bacteria, particularly Klebsiella pneumoniae and Escherichia 
coli. The co- infection/ co- colonisation rate >48 h after admis-
sion was 27.0 per 1000 person- days (95 % CI 21.3–34.1).
Comparison with literature
Concern regarding co- infection during viral pandemics, 
specifically respiratory co- infection with a bacterial pathogen, 
is borne from previous experience in influenza. During 
the 2009 H1N1 influenza A pandemic, early co- infection/ 
co- colonisation rates were high; 22.5 % within 72 h of 
admission in adults requiring critical care [18]. In contrast, 
limited evidence from studies of Severe Acute Respiratory 
Syndrome and Middle East Respiratory Syndrome suggest 
lower co- infection rates (10.3–18.5 %) [19, 20]. In COVID-
19, systematic reviews based on studies predominantly from 
China reported low estimates (<7 %) of bacterial co- infection 
[21–23]. In the UK, retrospective single- centre studies have 
observed low rates of bacterial co- infection [24–26]. Hughes 
et al. detected early bacterial infection (0–5 days from admis-
sion) in 3.2 % of all hospitalised patients (13.5 % of those 
requiring critical care), increasing to 6.1 % throughout admis-
sion [25]. Youngs et al. reported bacterial co- infection within 
48 h of admission to ICU in 8 % of patients with COVID-19 
compared to 58 % of patients with influenza, with no difference 
in the incidence of late infection between the two groups [26]. 
In the US, higher early bacterial co- infection rates (16.6 %) 
Fig. 2. Bacterial pathogens detected after 48 h of hospital admission; 124 potential pathogens detected. Reported as proportion (%) of 
the total number of bacterial pathogens detected within ‘3–7 days’ and ‘>7 days’ from hospital admission.
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were identified by Crotty et al.; respiratory cultures positive 
for oral bacteria flora constituted 15/25 of these cases [27]. 
In contrast to studies that relied on predominantly culture- 
based techniques, Kreitmann et al. identified early bacterial 
co- infection in 27.7 % (13/47) of their prospective cohort of 
ventilated patients using a multiplex PCR assay with only one 
case identified by conventional culture [28]. In France, a single 
centre study using three multiplex PCR assays performed on 
respiratory specimens or nasopharyngeal swabs in addition to 
standard culture techniques retrospectively identified bacte-
rial co- infection in 28 % of 92 ICU admissions [29]. Variations 
in case definitions, diagnostic testing and geography may 
partly account for the differences observed between studies 
although overall, there is a suggestion that increased severity 
of disease, particularly when ICU care is required, is associ-
ated with increased rates of co- infection.
The prevalence of nosocomial infection is 20.6 % and 
increases with duration of ICU stay [30, 31]. Our observed 
co- infection/ co- colonisation rate is relatively high, consistent 
with a patient cohort with long ICU stays (median 10 days) 
and requiring high levels of respiratory support.
Consistent with reports from other studies, the commonest 
potential co- infecting bacteria identified within 48 h of 
admission was S. aureus [25, 28, 32]. In patients in whom 
early co- infection is suspected clinically, due consideration 
of S. aureus is warranted. However, the rate of S. aureus 
co- infection is markedly lower than that observed in 
pandemic influenza, suggesting it is a less significant issue 
with COVID-19 infection [18]. The predominant late patho-
gens observed were Gram- negative bacteria, particularly 
K. pneumoniae. These pathogens are commonly associated 
with hospital and ventilator- acquired pneumonia and have 
been reported as common co- pathogens in COVID-19 
infections, particularly ICU cohorts [21, 22, 33–35]. The 
predominance of Gram- negative bacteria in these studies 
likely reflects nosocomial infection following prolonged ICU 
stay and empirical antibiotic use.
Viral co- pathogen was identified in one patient in our cohort; 
lower than the 3 % (95 % CI 1–6 %) viral co- infection rate 
reported in systematic reviews and in contrast to the 20.7 % 
viral co- detection rate reported by Kim et al. in Northern 
California [21, 36]. The 2019/20 influenza season in the UK 
ended in late March [37]. Other UK cohorts recruited during 
the spring wave of COVID-19 (March - May 2020) similarly 
reported very little or no viral co- infection [25, 35].
Strengths and limitations
This pragmatic multicentre study provides novel data on 
both community- acquired and nosocomial co- infection/ 
co- colonisation in patients with COVID-19 requiring ICU 
care in England. The ICU cohort represents those with severe 
disease who were subject to more rigorous microbiology 
sampling. A key limitation of the study is its retrospective 
observational design subject specifically to case selection, 
ascertainment and sampling biases. Inclusion of consecutive 
eligible patients was not feasible due to pandemic workload 
constraints. To minimise case selection bias, participating 
sites submitted a random sample of their eligible cohort, 
although random sampling methods were not standardised. 
The impact of ascertainment bias due to differences in the 
proportion of eligible cases submitted by each institution was 
reduced through the participation of multiple centres. The 
study cohort was comparable to the ICNARC cohort except 
for an under- representation of patients of Black, Asian and 
Minority Ethnicity (BAME). Our results may not be appli-
cable to settings with larger BAME populations. Restriction 
of our cohort to those with completed ICU admissions 
excluded: (i) frailer patients in whom ICU care was deemed 
Table 3. Univariate logistic regression analyses investigating the 
association between variables of interest and odds of developing co- 
infection/ co- colonisation
Crude OR (95% CI) p value
Number of patients
Age
  18–49 1 (Reference)
  50–64 2.28 (1.14–4.53) 0.019*
  65–74 1.12 (0.52–2.41) 0.777
  75–84 0.53 (0.18–1.61) 0.263
Gender
  Male 1 (Reference)
  Female 0.70 (0.40–1.23) 0.218
Ethnicity
  White 1 (Reference)
  Black 1.89 (0.77–4.62) 0.164
  Asian 0.77 (0.26–2.22) 0.625
  Mixed 1.64 (0.26–10.13) 0.597
  Other 1.84 (0.40–8.57) 0.437
  BAME† 1.36 (0.71–2.61) 0.349
  Unknown 1.73 (0.87–3.42) 0.117
Co- morbidities
  Cardiovascular –
  Respiratory –
  Renal 1.38 (0.23–8.43) 0.725
  Liver –
  Metastatic disease –
  Haematological malignancy 0.34 (0.04–2.83) 0.316
  Immunocompromise 0.36 (0.08–1.65) 0.187
  Type 2 diabetes mellitus 0.78 (0.42–1.44) 0.434
*p value of <0.05 denotes a significant difference # median and IQR.
†BAME is the total of Black, Asian, Mixed and Other ethnicities.
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not appropriate, and (ii) patients with very long ICU stays. 
Co- infection, particularly nosocomial infection, may be 
higher in these patients.
A second key limitation is that although results likely to repre-
sent contamination were excluded, some pathogens found in 
respiratory tract samples may represent colonisation rather 
than active co- infection. However, as sputum samples sent 
from ICU should reflect clinical concern of lower respiratory 
tract infection (especially during the pandemic timeframe) 
and positive culture represents predominant presence of a 
pathogen rather than as part of mixed flora, we have taken 
these results to represent infection. If colonising pathogens 
were wrongly attributed as causing infection, the direction 
of bias would be towards falsely higher co- infection rates 
observed in our study.
Thirdly, reliance on culture dependent techniques may have 
falsely decreased co- infection rates. Antibiotic use prior 
to admission was low (13.8 %), increasing the reliability of 
culture- based methods on admission. However, detection of 
pathogens later into admission would have been influenced by 
sampling bias and the use of empirical antibiotics. Fourthly, 
although seven hospitals participated in this study, one study 
site contributed a third of cases; observed 48 h co- infection/ 
co- colonisation rate excluding this site was, however, similar 
to overall results.
Implications for future work
Notwithstanding these limitations, our data indicate that early 
in hospitalisation, bacterial co- infection in COVID-19 is very 
uncommon and support the recommendations that empirical 
antibiotics should not be started routinely in primary care or 
at the point of hospital admission without clinical suspicion of 
bacterial infection [8]. The high rate of co- infection found late 
in illness among patients requiring ICU and involving noso-
comial pathogens is concerning. It is plausible that reducing 
unnecessary early antibiotic exposure in patients with 
COVID-19 could reduce their risk of late, Gram- negative, 
potentially antibiotic resistant infections [38, 39].
Since study completion, dexamethasone has been shown to 
decrease mortality in patients hospitalised with COVID-19 
who require oxygen support or invasive mechanical venti-
lation [40]. Consequently, dexamethasone has become 
established as standard of care for these patients in many 
countries. This may increase the already high rate of bacte-
rial co- infection we observed in ICU- treated patients. A high 
level of microbiological vigilance is recommended as part of 
the management of these patients. In the setting of seasonal 
changes in respiratory pathogens, ongoing surveillance for 
co- infections in patients hospitalised with COVID-19, ideally 
through prospective studies with standardised sampling 
protocols, is advised.
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